CCCC stock icon

C4 Therapeutics
CCCC

$5.48
0.72%
 

About: C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

Employees: 145

0
Funds holding %
of 6,665 funds
0
Analysts bullish %
of 6 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 2 (+1) [Q1 2024]

79% more capital invested

Capital invested by funds: $265M [Q4 2023] → $473M (+$208M) [Q1 2024]

48% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 25

13% more funds holding

Funds holding: 91 [Q4 2023] → 103 (+12) [Q1 2024]

7% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 27

6% more call options, than puts

Call options by funds: $3.71M | Put options by funds: $3.51M

10.7% less ownership

Funds ownership: 95.2% [Q4 2023] → 84.5% (-10.7%) [Q1 2024]

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$6
9%
upside
Avg. target
$10.17
86%
upside
High target
$14
155%
upside

6 analyst ratings

positive
50%
neutral
50%
negative
0%
Wells Fargo
Derek Archila
46%upside
$8
Equal-Weight
Maintained
9 May 2024
Stifel
Bradley Canino
155%upside
$14
Buy
Maintained
9 May 2024
Morgan Stanley
Terence Flynn
46%upside
$8
Equal-Weight
Maintained
26 Feb 2024
Stifel
Bradley Canino
137%upside
$13
Buy
Reiterated
23 Feb 2024
JP Morgan
Eric Joseph
9%upside
$6
Neutral
Upgraded
29 Jan 2024

Financial journalist opinion